Outlook Therapeutics, Inc. (OTLK) Tops Q2 EPS by 9c

Outlook Therapeutics, Inc. (NASDAQ: OTLK) reported Q2 EPS of ($0.89), $0.09 better than the analyst estimate of ($0.98).

For earnings history and earnings-related data on Outlook Therapeutics, Inc. (OTLK) click here.

You May Also Be Interested In

• Mosaic (MOS), Others Lower Following Trump Post on Potash from Belarus
• Strategy (MSTR) call put ratio 2.3 calls to 1 put as share price up 8.3%
• Raymond James Reiterates Outperform Rating on Verizon (VZ)